Compare · AKU vs ILMN
AKU vs ILMN
Side-by-side comparison of Akumin Inc. (AKU) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKU and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $40.46B, about 315.6x AKU ($128.2M).
- ILMN has hit the wire 8 times in the past 4 weeks while AKU has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 1 for AKU).
- Company
- Akumin Inc.
- Illumina Inc.
- Price
- $0.28-19.49%
- $262.52-2.06%
- Market cap
- $128.2M
- $40.46B
- 1M return
- -
- +7.01%
- 1Y return
- -
- +164.02%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 0
- 8
- Recent ratings
- 1
- 25
Akumin Inc.
Akumin Inc. provides outpatient diagnostic imaging services in the United States. Its centers offer physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The company provides various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures; and online medical bill payment services. As of December 31, 2020, the company operated 127 outpatient diagnostic imaging centers located in Florida, Texas, Pennsylvania, Delaware, Georgia, Illinois, and Kansas. Akumin Inc. is headquartered in Plantation, Florida.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest AKU
- SEC Form EFFECT filed by Akumin Inc.
- SEC Form SC 13G/A filed by Akumin Inc. (Amendment)
- SEC Form SC 13G filed by Akumin Inc.
- Akumin Announces Changes to Leadership Team
- SEC Form SC 13G/A filed by Akumin Inc. (Amendment)
- SEC Form SC 13G/A filed by Akumin Inc. (Amendment)
- SEC Form 15-12G filed by Akumin Inc.
- SEC Form S-8 POS filed by Akumin Inc.
- SEC Form POS AM filed by Akumin Inc.
- Akumin Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement, Regulation FD Disclosure
Latest ILMN
- Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- SEC Form 8-K filed by Illumina Inc.
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Illumina releases SpliceAI2 to help advance rare disease research
- SEC Form 4 filed by Illumina Inc.
- SEC Form SCHEDULE 13G filed by Illumina Inc.
- Director Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)
- Director Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)